Expanded Access for the Treatment of Cancers With Rearranged During Transfection (RET) Activation

Clinical trial NCT03906331 · APPROVED_FOR_MARKETING

Trial details

NCT number: NCT03906331
Sponsor: Eli Lilly and Company
Status: APPROVED_FOR_MARKETING
Study type: EXPANDED_ACCESS

Non Small Cell Lung Cancer Medullary Thyroid Cancer Colon Cancer Breast Cancer Pancreatic Cancer Papillary Thyroid Cancer Other Solid Tumors With Evidence of Activating RET Alteration

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.